OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Jesus Alfonso Catahay, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 43-58
Closed Access | Times Cited: 23
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Jesus Alfonso Catahay, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 43-58
Closed Access | Times Cited: 23
Showing 23 citing articles:
Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Raymart Macasaet, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1044-1052
Closed Access | Times Cited: 14
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Raymart Macasaet, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1044-1052
Closed Access | Times Cited: 14
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 5
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 5
Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study
Anna Camporesi, Rosa Morello, Anna Rocca, et al.
EClinicalMedicine (2024) Vol. 76, pp. 102815-102815
Open Access | Times Cited: 5
Anna Camporesi, Rosa Morello, Anna Rocca, et al.
EClinicalMedicine (2024) Vol. 76, pp. 102815-102815
Open Access | Times Cited: 5
Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity
Orsolya Mózner, Edit Szabó, Anna Kulin, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316396-e0316396
Open Access
Orsolya Mózner, Edit Szabó, Anna Kulin, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316396-e0316396
Open Access
Prevalence and risk factors for long COVID in China: a systematic review and meta-analysis of observational studies
Le-Yan Hu, A. Cai, Bo Li, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 3, pp. 102652-102652
Open Access
Le-Yan Hu, A. Cai, Bo Li, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 3, pp. 102652-102652
Open Access
A Machine-Learning Approach to Finding Gene Target Treatment Options for Long COVID
Alejandro Lopez‐Rincon
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Alejandro Lopez‐Rincon
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 3
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 3
Acute COVID-19 treatment is not associated with health problems 2 years after hospitalization
Julia C. Berentschot, L. Martine Bek, Majanka H. Heijenbrok–Kal, et al.
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106966-106966
Open Access | Times Cited: 2
Julia C. Berentschot, L. Martine Bek, Majanka H. Heijenbrok–Kal, et al.
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106966-106966
Open Access | Times Cited: 2
The importance of including Long COVID outcomes when developing novel treatments for acute COVID-19
Chloe Connor, Holly A. Taylor
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Chloe Connor, Holly A. Taylor
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome
Simon Haunhorst, Diana Dudziak, Carmen Scheibenbogen, et al.
Infection (2024)
Open Access | Times Cited: 2
Simon Haunhorst, Diana Dudziak, Carmen Scheibenbogen, et al.
Infection (2024)
Open Access | Times Cited: 2
Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Falko Tesch, Franz Ehm, Friedrich Loser, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Falko Tesch, Franz Ehm, Friedrich Loser, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Does PI-ME/CFS recall post-COVID (PASC) syndrome?
Salvatore Chirumbolo, Marianno Franzini, Umberto Tirelli
Virus Research (2024) Vol. 345, pp. 199393-199393
Open Access | Times Cited: 1
Salvatore Chirumbolo, Marianno Franzini, Umberto Tirelli
Virus Research (2024) Vol. 345, pp. 199393-199393
Open Access | Times Cited: 1
Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent
Falko Tesch, Franz Ehm, Friedrich Loser, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Falko Tesch, Franz Ehm, Friedrich Loser, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Lights and Shadows of Long COVID: Are Latent Infections the Real Hidden Enemy?
Francesca Serapide, Marisa Talarico, Salvatore Rotundo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7124-7124
Open Access | Times Cited: 1
Francesca Serapide, Marisa Talarico, Salvatore Rotundo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7124-7124
Open Access | Times Cited: 1
Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity
Orsolya Mózner, Edit Szabó, Anna Kulin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Orsolya Mózner, Edit Szabó, Anna Kulin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Vitamin D Deficiency And Risk Of COVID-19 Infection
Ozdan Akram Ghareeb, Goljameen Midhat Abdulla, Awni Ismail Sultan
INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH (2024) Vol. 03, Iss. 05
Open Access
Ozdan Akram Ghareeb, Goljameen Midhat Abdulla, Awni Ismail Sultan
INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH (2024) Vol. 03, Iss. 05
Open Access
Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?
César Fernández‐de‐las‐Peñas, Anabel Franco‐Moreno, María Ruiz‐Ruigómez, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 947-947
Open Access
César Fernández‐de‐las‐Peñas, Anabel Franco‐Moreno, María Ruiz‐Ruigómez, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 947-947
Open Access
Comparative analysis of financial toxicity between SARS-CoV-2 infection and common comorbidities
Han Su, Hilaire J. Thompson, Karl Cristie Figuracion, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0309116-e0309116
Open Access
Han Su, Hilaire J. Thompson, Karl Cristie Figuracion, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0309116-e0309116
Open Access
Molecular targets in SARS-CoV-2 infection: an update on repurposed drug candidates
Dibachehr Rahmani, Ameneh Jafari, Prashant Kesharwani, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155589-155589
Closed Access
Dibachehr Rahmani, Ameneh Jafari, Prashant Kesharwani, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155589-155589
Closed Access
Defining long COVID using a population-based SARS-CoV-2 survey in California
Jake M. Pry, Kalyani McCullough, Kristina Lai, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126358-126358
Open Access
Jake M. Pry, Kalyani McCullough, Kristina Lai, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126358-126358
Open Access
A nomogram to predict long COVID risk based on pre- and post-infection factors: Results from a cross-sectional study in South China
Meng Zhou, Qicheng Zhu, Yucheng Xu, et al.
Public Health (2024) Vol. 237, pp. 176-183
Closed Access
Meng Zhou, Qicheng Zhu, Yucheng Xu, et al.
Public Health (2024) Vol. 237, pp. 176-183
Closed Access
Influence of smoking and obesity on post-COVID-19 sequelae and risk of hospitalization
Daniel Fernández-Pedruelo, Raúl Juárez‐Vela, Regina Ruiz de Viñaspre‐Hernández, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Daniel Fernández-Pedruelo, Raúl Juárez‐Vela, Regina Ruiz de Viñaspre‐Hernández, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
